NEEDHAM, Mass., Apr 16, 2008 (BUSINESS WIRE) -- AVANT Immunotherapeutics, Inc. (AVAN) will hold a conference call today at 5:00 PM ET to discuss today's announcement of an exclusive worldwide licensing and development agreement between AVANT, acting through its wholly-owned subsidiary Celldex Therapeutics, Inc., and Pfizer for CDX-110. CDX-110, a therapeutic cancer vaccine candidate, is in Phase 2 development for the treatment of glioblastoma multiforme (GBM).
To access the live call, dial 866-383-8009 (within the United States) or 617-597-5342 (outside the United States). The passcode for participants is 83919284. The call will also be available live on the Company's website www.avantimmune.com in the Investor Information, Investor Overview section.
A replay will be available approximately two hours after the live call until April 23, 2008. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The replay passcode is 71323547. The replay will also be available on the Company's website www.avantimmune.com .
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics and Celldex Therapeutics combined during the first quarter of 2008. AVANT is a NASDAQ-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel "targeted immunization" approach. In addition, AVANT is exploiting its access to proprietary human antibody technology for development of therapeutic monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of products in varying stages of development. Identification of the potential of EGFRvIII in cancer diagnosis, prevention and therapy was based on the collaborative efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Application of this discovery toward the development of the CDX-110 vaccine was further advanced by Dr. John Sampson and his colleagues at the Duke University Brain Tumor Center in collaboration with Dr. Amy Heimberger at the MD Anderson Cancer Center. AVANT also has several product candidates in its development pipeline including:
-- CDX-1307, a product based on its proprietary APC Targeting Technology(TM), which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast and colon cancer;
-- TP10, a complement inhibitor, in development for transplantation and other indications; and
-- Three candidates based on its oral, rapidly-protecting, single-dose and temperature-stable vaccine technology, including combination vaccines for travelers, the military and global health needs.
AVANT has three commercialized products, including Rotarix(R) (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs. For more information on AVANT or Pfizer or please visit www.avantimmune.com or www.pfizer.com .